Klivira
Request demo

Streamlining Aetna Toujeo Prior Authorization

Effectively managing Aetna Toujeo prior authorization is critical for ensuring timely patient access to this long-acting insulin. Klivira streamlines the process by connecting directly with Aetna's systems.

For revenue cycle directors and prior authorization coordinators, navigating payer-specific requirements for high-volume medications like Toujeo can be complex. Understanding Aetna's submission channels, policy criteria, and appeal pathways is key to minimizing delays and denials for patients with diabetes.

Aetna Toujeo Prior Authorization Submission Channels

Toujeo, a long-acting insulin glargine used for Type 1 and Type 2 diabetes, typically falls under Aetna's pharmacy benefit, administered by CVS Caremark. Prior authorization requests for Toujeo are primarily routed through electronic prior authorization (ePA) partners like CoverMyMeds or Surescripts for retail pharmacies, or directly via CVS Caremark's provider portal for mail-order scenarios.

Understanding Aetna's Policy for Toujeo

Aetna publishes its medical necessity criteria, including those for pharmacy benefits, within its Clinical Policy Bulletins (CPBs). These CPBs outline specific requirements such as diagnosis confirmation, previous treatment failures (step therapy), and quantity limits. Providers must consult the relevant, versioned CPB for Toujeo to ensure compliance and support medical necessity.

Common Denial Reasons for Toujeo with Aetna

Denials for Toujeo prior authorizations frequently stem from insufficient clinical documentation failing to meet Aetna's medical necessity criteria, or non-adherence to step therapy protocols. Other reasons may include dose maximums exceeding policy limits or lack of documented failure with required preceding therapies. These denials are communicated via X12 835/277 transactions or portal updates, utilizing CARC and RARC vocabularies.

Key Considerations for Timely Aetna Toujeo Approvals

  • Utilize ePA channels (CoverMyMeds, Surescripts) for pharmacy benefit submissions to expedite processing.
  • Ensure all clinical documentation precisely aligns with the latest Aetna Clinical Policy Bulletin (CPB) for Toujeo.
  • Be aware of state-mandated turnaround times for commercial plans, which vary significantly.
  • For Aetna Medicare Advantage plans, adhere to CMS-0057-F requirements for 72-hour standard and 24-hour expedited decisions.
  • Proactively address any step therapy requirements outlined in Aetna's CPBs by documenting prior treatment failures.

Aetna Toujeo Appeal Pathways

Should a Toujeo prior authorization be denied, Aetna provides structured appeal pathways documented in its provider manual. These typically include reconsideration, peer-to-peer review, and formal appeals. Expedited appeal options are available for urgent clinical situations, and timely filing for appeals is crucial, with windows varying by line of business and state regulations.

Frequently asked questions

What is the primary submission channel for Toujeo prior authorizations with Aetna?

For Toujeo, which is typically a pharmacy benefit drug, the primary submission channels are electronic prior authorization (ePA) platforms like CoverMyMeds or Surescripts for retail pharmacies, or directly through the CVS Caremark provider portal for mail-order prescriptions.

Where can I find Aetna's medical necessity criteria for Toujeo?

Aetna's specific medical necessity criteria for medications like Toujeo are published in their Clinical Policy Bulletins (CPBs). These documents, available in the public Aetna CPB library, detail requirements such as diagnosis, step therapy, and quantity limits.

Does CMS-0057-F impact Toujeo prior authorizations for Aetna members?

Yes, for Aetna Medicare Advantage and Medicaid managed care plans, CMS-0057-F mandates 72-hour decisions for standard prior authorizations and 24-hour decisions for expedited requests. This rule does not directly apply to Aetna's commercial plans.

What are common reasons for Aetna to deny Toujeo prior authorizations?

Common denial reasons include insufficient clinical documentation to support medical necessity, failure to meet step therapy requirements, or exceeding prescribed quantity limits as outlined in Aetna's Clinical Policy Bulletins. Reviewing these CPBs thoroughly can help prevent denials.

What is the process for appealing a denied Toujeo prior authorization with Aetna?

Aetna's appeal process for denied prior authorizations typically involves reconsideration, followed by peer-to-peer review, and then a formal appeal. Expedited appeal options are available for urgent cases, with specific timely filing windows that vary by plan and state.

Related coverage

Other toujeo prior authorization by payer

Other toujeo prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo